Linked Data API

Show Search Form

Search Results

1127500
star this property registered interest false more like this
star this property date less than 2019-05-20more like thismore than 2019-05-20
star this property answering body
Department of Health and Social Care remove filter
star this property answering dept id 17 more like this
star this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading National Institute for Health and Care Excellence remove filter
unstar this property house id 1 more like this
star this property legislature
25259
star this property pref label House of Commons more like this
star this property question text To ask the Secretary of State for Health and Social Care, when NICE will publish the outcome of the NICE Evaluation Committee meeting held on 6 March 2019. more like this
star this property tabling member constituency West Lancashire more like this
star this property tabling member printed
Rosie Cooper remove filter
star this property uin 256255 more like this
star this property answer
answer
unstar this property is ministerial correction false remove filter
star this property date of answer less than 2019-05-29more like thismore than 2019-05-29
star this property answer text <p>Discussions about managed access agreements for technologies undergoing assessment by the National Institute for Health and Care Excellence (NICE) are rightly held between NHS England as an independent body and the manufacturer concerned. Departmental officials play no role in such discussions, but are in regular contact with NICE and NHS England colleagues about a range of issues, including progress in discussions about a potential managed access agreement for Spinraza (nusinersen) for the treatment of spinal muscular atrophy. Ministers have also held meetings with Biogen, NICE and NHS England on a number of occasions, at which the availability of Spinraza was discussed.</p><p> </p><p>NHS England and NICE have made stakeholders and the public aware of the outcome of its appraisal committee meeting of 8 May and NICE is now able to recommend the use of Spinraza for NHS patients in England, subject to a managed access agreement agreed between NHS England and Biogen which makes Spinraza available to children with the most severe form of spinal muscular atrophy available with immediate effect. NICE’s Appraisal Committee’s considerations and recommendations will be contained in the final appraisal document which will be published in due course, with final guidance expected in June 2019.</p>
star this property answering member constituency South Ribble more like this
unstar this property answering member printed Seema Kennedy more like this
star this property grouped question UIN 256254 more like this
star this property question first answered
less than 2019-05-29T10:38:01.217Zmore like thismore than 2019-05-29T10:38:01.217Z
star this property answering member
4455
star this property label Biography information for Seema Kennedy more like this
star this property tabling member
1538
star this property label Biography information for Rosie Cooper more like this